

# DMICC

## DIABETES MELLITUS INTERAGENCY COORDINATING COMMITTEE (DMICC) Psychoactive Drugs and Type 2 Diabetes

Bethesda Marriott Suites

8:30 a.m.–3:30 p.m.

September 18, 2006

### *DRAFT AGENDA*

---

8:30–8:40 a.m.	Welcome and Introductions	Judy Fradkin and Griff Rodgers National Institute of Diabetes and Digestive and Kidney Diseases
----------------	---------------------------	-------------------------------------------------------------------------------------------------------

#### SESSION I: OVERVIEW OF THE PROBLEM

8:40–8:45 a.m.	Moderator	Mark Chavez National Institute of Mental Health
----------------	-----------	----------------------------------------------------

8:45–9:30 a.m.	Disorders, Drugs, Metabolic Outcomes	John Newcomer Washington University in St. Louis
----------------	--------------------------------------	-----------------------------------------------------

9:30–10:00 a.m.	Discussant	Samuel Dagogo-Jack University of Tennessee, Memphis
-----------------	------------	--------------------------------------------------------

**Discussion points including areas of consensus and contention: TBA**

10:00–10:15 a.m.	<b>BREAK</b>
------------------	--------------

#### SESSION II: PSYCHOACTIVE DRUGS AND THEIR METABOLIC OUTCOMES

10:15–10:20 a.m.	Moderator	Sanford Garfield National Institute of Diabetes and Digestive and Kidney Diseases
------------------	-----------	-----------------------------------------------------------------------------------------

10:20–10:55 a.m.	Mechanisms and Pathogenesis	Marilyn Ader Keck School of Medicine
------------------	-----------------------------	-----------------------------------------

10:55–11:30 a.m.		Richard Bergman Keck School of Medicine
------------------	--	--------------------------------------------

**11:30–12:00 noon**    **Discussant**    John Newcomer  
Washington University in St. Louis

**Discussion points including areas of consensus and contention: TBA**

**12:00 noon–1:00 p.m.**    **LUNCH (on your own)**

**SESSION III: PREVENTION AND TREATMENT**

**1:00–1:05 p.m.**    **Moderator**    Richard Rubin  
Johns Hopkins University School of Medicine

**1:05–1:50 p.m.**    **Drugs and Lifestyle Intervention**    Tony Cohn  
University of Toronto

**1:50–2:30 p.m.**    **Discussant**    Richard Rubin  
Johns Hopkins University School of Medicine

**Discussion points including areas of consensus and contention: TBA**

**2:30–3:30 p.m.**    **SESSION IV: PANEL DISCUSSION: KEY UNANSWERED QUESTIONS  
AND COMPELLING RESEARCH OPPORTUNITIES**

**Moderator**    Judy Fradkin  
National Institute of Diabetes and Digestive  
and Kidney Diseases

**Panel Members:** (5 minutes for each panel member, then discussion)

Michael J. Sernyk, Yale University School of Medicine

Rohan Ganguli, University of Pittsburgh

Gail Daumit, Johns Hopkins University

Nathaniel Clark, American Diabetes Association

Brian Kirkpatrick, Medical College of Georgia

Mary Parks, U.S. Food and Drug Administration

**3:30 p.m.**    **Closing Remarks and Adjournment**    Judy Fradkin  
National Institute of Diabetes and Digestive  
and Kidney Diseases